In an initial proof-of-concept (POC) study with 13 APOE4 positive AD patients with mild cognitive impairment (MCI), obicetrapib decreased plasma and cerebrospinal fluid levels (CSF) of 24S- and 27-hydroxycholesterol, increased levels of critical lipophilic antioxidants and carotenoids, and stabilized key biomarkers associated with AD. The gene discussed is APOE; the disease is Alzheimer disease.